{"id":31054,"date":"2026-03-30T16:00:30","date_gmt":"2026-03-30T14:00:30","guid":{"rendered":"https:\/\/www.neolifesalud.com\/blog\/uncategorized\/how-our-understanding-of-cholesterol-and-cardiovascular-risk-is-changing\/"},"modified":"2026-03-30T16:00:30","modified_gmt":"2026-03-30T14:00:30","slug":"how-our-understanding-of-cholesterol-and-cardiovascular-risk-is-changing","status":"publish","type":"post","link":"https:\/\/www.neolifesalud.com\/en\/blog\/neolife-en\/how-our-understanding-of-cholesterol-and-cardiovascular-risk-is-changing\/","title":{"rendered":"How Our Understanding of Cholesterol and Cardiovascular Risk Is Changing"},"content":{"rendered":"
\n

The recently published American guidelines for the management of dyslipidemia reinforce an important shift in how we understand cardiovascular risk. This is not so much about new targets, but about a more precise way of interpreting what is actually happening in each patient. <\/h1>\n

For many years, dyslipidemia has been understood as an alteration in numbers: elevated LDL cholesterol implied increased risk, and reducing it was the primary treatment goal. While useful, this approach oversimplifies a much more complex process. <\/p>\n

Dr. Carlos Mart\u00ed \u2013 Neolife Medical Team<\/em><\/p>\n

\n

Cardiovascular Prevention<\/strong><\/p>\n

For a long time, the focus has been on identifying out-of-range values. However, we now know that the atherosclerotic process (the accumulation of fat in the arteries) begins long before these values change or symptoms appear. <\/p>\n

This explains why some individuals experience cardiovascular events despite having apparently normal blood tests, while others with elevated levels remain stable for years. The difference lies in what is not always visible in conventional testing: particle number, cumulative burden, or the presence of subclinical disease. Today\u2019s tools allow access to this information and enable a better understanding of where each patient stands in the disease process. <\/p>\n

The goal, therefore, is not only to detect abnormalities once they become evident, but to interpret earlier signals that allow for more proactive intervention. In cardiovascular health<\/strong>, it is not just about treating risk when it appears, but about understanding how it develops from much earlier stages. <\/p>\n

Beyond Cholesterol: Understanding What We Really Measure <\/strong><\/p>\n

LDL cholesterol<\/strong> has traditionally been the cornerstone of diagnosis and treatment. However, not all LDL particles have the same impact, and a normal value does not guarantee low risk. In this context, apolipoprotein B (ApoB)<\/strong> has gained importance. It is a protein present in all particles capable of forming plaques in the arteries, meaning that measuring it is essentially counting how many \u201cpotentially harmful particles\u201d are circulating in the bloodstream. <\/p>\n

Unlike LDL, which measures how much cholesterol<\/strong> these particles carry, ApoB indicates how many particles are actually present. This is particularly useful in individuals with overweight, diabetes, or elevated triglycerides, where LDL may appear normal despite high risk. <\/p>\n

\"cholesterol\"<\/p>\n

But not all risk depends on lifestyle<\/strong> or metabolism. There is also a genetic component that may go unnoticed in standard blood tests. This is where lipoprotein(a), or Lp(a), becomes relevant. It is a particle similar to LDL but with unique characteristics that make it especially atherogenic (more likely to promote plaque formation in the arteries). Its levels are largely genetically determined, meaning a person may have elevated Lp(a) from birth without knowing it. As a result, even with apparently normal cholesterol levels, cardiovascular risk may be higher than expected if Lp(a) is elevated. For this reason, current guidelines recommend measuring it at least once in a lifetime. <\/p>\n

The integration of these biomarkers provides a more comprehensive assessment of risk, moving beyond a model based solely on total cholesterol or LDL.<\/p>\n

From Estimating Risk to Detecting Disease <\/strong><\/p>\n

Another key change reinforced by the new guidelines is the use of imaging techniques to refine risk assessment in selected patients. Coronary artery calcium (CAC) measures the amount of calcium deposited in the arteries of the heart. Its presence indicates that atherosclerosis already exists, even in the absence of symptoms. <\/p>\n

Although not yet part of the main guideline recommendations, carotid ultrasound allows direct visualization of the neck arteries and the detection of plaques or arterial wall thickening (intima-media thickness, IMT, a marker of arterial health). While CAC identifies more advanced disease, carotid ultrasound can provide information about earlier stages of the process. <\/p>\n

At Neolife<\/strong>, these tools are part of an advanced preventive medicine<\/strong> approach. This allows for more precise adjustment of treatment intensity and prioritization of interventions in patients who might otherwise appear low-risk based on conventional testing. <\/p>\n

We combine biomarkers such as ApoB<\/strong> and lipoprotein(a)<\/strong> with imaging techniques, including carotid ultrasound, to obtain a more complete picture of vascular health. The goal is not only to estimate future risk, but to determine whether the disease process has already begun\u2014even in its earliest stages. <\/p>\n

\"cholesterol\"<\/p>\n

A More Precise, Not More Complex Approach <\/strong><\/p>\n

The evolution in dyslipidemia management does not mean performing more tests on every patient, but rather selecting more effectively which information is needed in each case.<\/p>\n

In practice, this translates into:<\/p>\n